Présentation de l'entreprise
Mustang Bio, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to translating advanced cell therapies into potential cures for challenging-to-treat cancers and autoimmune conditions within the United States market. The company functions within the healthcare sector, specifically under the biotechnology industry classification, which implies a focus on high-risk, high-reward research and development activities rather than established product sales. In terms of scale, the organization maintains a market capitalization of $5.68M, reports no annual revenue figures as indicated by N/A, and employs a workforce of 4 individuals. The combination of a market cap of $5.68M and a reported revenue of N/A suggests that the company is in a pre-revenue or early-stage development phase where value is derived primarily from intellectual property and pipeline potential rather than current commercial operations. This limited operational scale is typical for clinical-stage firms that are currently allocating resources toward advancing their therapeutic candidates, such as MB-106, through various phases of clinical trials.
Santé financière
The company reports N/A for revenue over the trailing twelve months, a net income of $-1,921,000, and an EBITDA of $-2,398,000. The absence of revenue paired with a net loss of $-1,921,000 reveals a cost structure driven almost entirely by research and development expenditures rather than cost of goods sold or operating expenses linked to sales. The free cash flow stands at $-4,149,000, indicating that the company is consuming significant cash reserves to fund its operations and clinical trials, which limits immediate financial flexibility but is a common characteristic of biotechnology firms in the clinical stage. All three margins are reported at 0.0%, specifically the gross margin, operating margin, and profit margin; these figures indicate that without commercial revenue, traditional profitability metrics are not applicable or are negative in a way that renders them effectively zero in reporting systems. The company holds $17.27M in cash against $0 in debt, resulting in a debt-to-equity ratio listed as N/A, which suggests a balance sheet that is highly conservative and free of financial leverage obligations. The current ratio is 2.22, indicating that the company possesses sufficient liquid assets to cover its short-term liabilities more than twice over, providing a buffer against cash burn. Return on Equity is -67.9% and Return on Assets is -11.3%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, reflecting the capital-intensive nature of developing cell therapies.
Évaluation de la valorisation
The trailing twelve-month P/E ratio is N/A, while the forward P/E is -2.14; the distinction between these figures implies that analysts are pricing in future earnings potential that is currently obscured by the company's present lack of profitability. The price-to-book ratio is 0.57, indicating that the market values the company at less than half of its net asset book value, which may reflect skepticism regarding the recoverability of its intangible assets or the likelihood of the clinical pipeline succeeding. The price-to-sales ratio is N/A and the EV/EBITDA is 4.83; these alternative valuation metrics suggest that investors are relying on enterprise value multiples that account for the company's cash position rather than earnings power. The 52-week high is $7.00 and the 52-week low is $0.53, placing the current trading price within a range where the stock has demonstrated extreme volatility over the last year. The beta value is 2.18, meaning the stock's price volatility is significantly higher than the broader market, likely moving with greater intensity than the S&P 500 due to its specific biotechnology sector risks and small market capitalization.
Growth & Income
The revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, meaning that without established historical sales data, it is impossible to calculate growth rates or determine if earnings are growing faster or slower than revenue. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm reinvests all available resources and earnings retention into its growth initiatives rather than distributing income to shareholders. Since the company does not pay dividends, the entire financial strategy focuses on capitalizing on growth opportunities through clinical advancement rather than providing immediate income returns. The overall growth and income profile is characterized by a complete absence of current commercial metrics and dividend distributions, relying entirely on the successful translation of cell therapies into marketable cures for future revenue generation.